Unfit patients also have the alternative of venetoclax additionally obinutuzumab (VO) as frontline therapy. This relies with a section III demo that as opposed VO with ClbO in aged/unfit patients.113 VO was exceptional regarding response price and progression-totally free survival, and experienced a similar safety profile. In this particular trial